InterMune prices Esbriet in Germany and Norway and raises $231m in equity and loans
This article was originally published in Scrip
Executive Summary
From 14 September, InterMune's Esbriet (pirfenidone) will be available in its first European market, Germany, as a treatment for mild to moderate idiopathic pulmonary fibrosis (IPF) in adults. The product has been priced at €51,000 in Germany and over €35,000 in Norway.